Vera Therapeutics Inc (VERA)
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing treatments for patients with immunological diseases. Its lead program, atacicept, is a fully humanized TACI-Fc fusion protein designed to target BAFF and APRIL and is being studied as a self-administered subcutaneous therapy for immunoglobulin A nephropathy and other autoimmune kidney diseases. The company is also advancing MAU868, a human monoclonal antibody for BK viremia infections that has completed phase 2 testing, as well as VT-109, a BAFF/APRIL dual-inhibitor BCMA molecule under development for B cell-mediated autoimmune diseases. Vera Therapeutics was incorporated in 2016, changed its name from Trucode Gene Repair, Inc. in April 2020, and is headquartered in Brisbane, California. Its common stock trades on the NASDAQ under the symbol VERA.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VERA
|
$44.96
|
22.0% Upside
|
Undervalued
|
$81.79
|
121.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-7.2x
|
5.3x
|
—
|
2.655 B
|
2.143 B
|
2.8%
|
72.4%
|
10.1
|
—
|
79.6%
|
